Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
about
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsMechanisms of altered redox regulation in neurodegenerative diseases--focus on S--glutathionylationSumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesisCommon factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous systemEpigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalitiesValproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitroMetabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-β-carboline by oxidative enzymes.Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties.Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.Systemic administration of valproic acid and zonisamide promotes differentiation of induced pluripotent stem cell-derived dopaminergic neurons.Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease.Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway.Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.Targeting histone deacetylases: a novel approach in Parkinson's disease.Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.Epigenetic regulation in Parkinson's disease.Can Valproic Acid Regulate Neurogenesis from Nestin+ Cells in the Adult Midbrain?Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells.The MPTP Story.Valproic acid-mediated inhibition of trimethyltin-induced deficits in memory and learning in the rat does not directly depend on its anti-oxidant properties.Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease.Genetics and epigenetics of Parkinson's disease.Epigenetic Study in Parkinson's Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain
P2860
Q24626017-CBABAC97-9BFF-46E2-86F1-F266D752FD96Q26772307-9AE720AA-9C67-45BE-AB54-D3FBA6E66268Q26830954-6F899A56-2A34-4ABE-918A-FA5A6FA6B595Q26866679-2DC69F9D-6399-4102-AF46-1DCC130C29F6Q27010627-8E5C27B0-B419-4ABC-8F44-5CC88AEC2629Q27023811-2589230A-046A-45B1-93EE-0D963AF3B19BQ34231640-04B2D1E3-0A90-4BED-946D-0C9DCD027390Q34655711-4F268D7F-50C7-4188-9CB7-4B4357697849Q35623461-0DB2FAD0-7D4A-4970-8312-00D33C77C9BBQ35858443-AA47CCAA-A6F8-4487-B3F2-470700ECAE3CQ35978159-ED2838C1-6512-411F-8EB0-CA1E671375CCQ36613561-7785E4FB-C84E-4B26-A347-C5AA2DEABA10Q37040889-55CA1A53-13A8-4E44-BE9A-E6443E6EAA94Q37548320-A260C253-0F58-4467-A6AA-66ED4B41BC1CQ37737705-FD1DE7C2-B7AE-4A4D-BA16-21126FAD8B9BQ38085375-3720580E-DE3A-4645-A954-E1201C5CADF0Q38361065-FA7F1310-E060-46B9-8537-085A021C1E9AQ38696371-9C696611-5AD0-4333-85FC-E5FC6AC015CEQ38766912-9C79D84E-DDD5-4D2A-9DDB-193AED6ECD27Q38881221-5958C466-902B-45EC-B6CC-045524787214Q39156635-F7B93617-EFFD-4DF2-AB3E-FD10EBCAA3D3Q39196413-1F21E0F0-3BF8-4F89-8182-69E9A97AB94CQ40759909-0EAA409C-7C24-4CD6-BBAE-4416B5CB4559Q41365481-542914D3-0A47-4A19-9875-BC263BD06B65Q41825283-16F73E66-AC6E-4EC7-A832-394F9BF283ECQ48351124-5DDC0FFC-383A-4CC5-B363-8751130D2D68Q48635091-4FDFE208-52DC-4A77-A6FA-11F415B38226Q48685306-29A30BF6-3F50-4CE3-B999-B7ADE5EF6A2AQ53375184-6199F715-3640-408E-8559-2A6BE1BDF6E4Q58693508-EF2829B7-E430-4133-8A88-D998ED79624C
P2860
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Protective effects of valproic ...... e model of Parkinson's disease
@ast
Protective effects of valproic ...... e model of Parkinson's disease
@en
type
label
Protective effects of valproic ...... e model of Parkinson's disease
@ast
Protective effects of valproic ...... e model of Parkinson's disease
@en
prefLabel
Protective effects of valproic ...... e model of Parkinson's disease
@ast
Protective effects of valproic ...... e model of Parkinson's disease
@en
P2860
P1433
P1476
Protective effects of valproic ...... e model of Parkinson's disease
@en
P2093
J S Schneider
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2011.08.010
P407
P577
2011-08-06T00:00:00Z